{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:16:18Z","timestamp":1767860178363,"version":"3.49.0"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology Communications"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clicom.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T11:42:32Z","timestamp":1652528552000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Covid-19 Vaccine safety and adverse event analysis from Pakistan"],"prefix":"10.1016","volume":"2","author":[{"given":"Syed Shahzad","family":"Hasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdur","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundus","family":"Osama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zia Ul","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7668-5013","authenticated-orcid":false,"given":"Hamid A.","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clicom.2022.05.003_bib0001","unstructured":"Uppsala reports. From tragedy Pakistan builds vibrant safety system. Accessed from URL: https:\/\/www.uppsalareports.org\/articles\/from-tragedy-pakistan-builds-vibrant-safety-system\/. Accessed November 6, 2020."},{"key":"10.1016\/j.clicom.2022.05.003_bib0002","unstructured":"World Health Organization (WHO). Deadly medicines contamination in Pakistan. Accessed from URL: https:\/\/www.who.int\/features\/2013\/pakistan_medicine_safety\/en\/. Accessed November 6, 2020."},{"key":"10.1016\/j.clicom.2022.05.003_bib0003","unstructured":"Drug Regulatory Authority of Pakistan (DRAP). Pakistan national pharmacovigilance guidelines. Accessed from URL: https:\/\/www.dra.gov.pk\/. Accessed November 9, 2020."},{"key":"10.1016\/j.clicom.2022.05.003_bib0004","unstructured":"Drug Regulatory Authority of Pakistan (DRAP). Med Safety Mobile Application. Accessed from URL: https:\/\/www.dra.gov.pk\/docs\/Lauch%20of%20Med%20Safety%20Mobile%20App.pdf Accessed November 6, 2020."},{"key":"10.1016\/j.clicom.2022.05.003_bib0005","unstructured":"The Nation. DRAP launches \u2018MED safety mobile app\u2019 to report drug reaction cases. Accessed from URL: https:\/\/nation.com.pk\/03-Nov-2020\/drap-launches-med-safety-mobile-app-to-report-drug-reaction-cases?show=preview Accessed November 9, 2020."},{"key":"10.1016\/j.clicom.2022.05.003_bib0006","unstructured":"Coronavirus Vaccine - weekly summary of Yellow Card Reporting By Medicines and Healthcare products Regulatory Agency in UK. Accessed from URL, https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting, Accessed: October 28, 2021."},{"key":"10.1016\/j.clicom.2022.05.003_bib0007","series-title":"Vaxzevria, Summary of Product Characteristics","year":"2022"}],"container-title":["Clinical Immunology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772613422000154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772613422000154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:53:29Z","timestamp":1757418809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772613422000154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":7,"alternative-id":["S2772613422000154"],"URL":"https:\/\/doi.org\/10.1016\/j.clicom.2022.05.003","relation":{},"ISSN":["2772-6134"],"issn-type":[{"value":"2772-6134","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Covid-19 Vaccine safety and adverse event analysis from Pakistan","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clicom.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}